Eli Lilly To Buy Back Cymbalta Rights For $400M
Eli Lilly & Co. said Monday it would repurchase the rights from Boehringer Ingelheim GmbH to develop and market antidepressant Cymbalta in countries outside of the U.S. and Japan, for an...To view the full article, register now.
Already a subscriber? Click here to view full article